PTC Therapeutics, Inc. - Common Stock — 현금 흐름 (NASDAQ:PTCT)

Financials

영업활동으로 인한 현금 -194.07 M-251.33 M-356.65 M-158.42 M-107.69 M711.2 M -217.95 M 투자 활동으로 인한 현금 -561.55 M219.18 M290.18 M-176.74 M44.18 M-861.98 M -771.36 M 재무활동으로 인한 현금 668.72 M20.88 M167.95 M646.4 M255.87 M331.09 M 328.09 M 잉여 현금 흐름 -194.07 M-251.33 M-356.65 M-158.42 M-107.69 M411.18 M -516.78 M

PTC Therapeutics, Inc. - Common Stock

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.

PTCT

Financials

PTC Therapeutics, Inc. - Common Stock

뉴스

Leqembi Isn’t Enough To Save Biogen Momentum (NASDAQ:BIIB)

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release